Monopar Therapeutics (MNPR) Cash from Operations: 2017-2020
Historic Cash from Operations for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to -$1.3 million.
- Monopar Therapeutics' Cash from Operations fell 112.07% to -$1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.1 million, marking a year-over-year decrease of 42.61%. This contributed to the annual value of -$6.4 million for FY2024, which is 18.50% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Cash from Operations is -$1.3 million, which was down 30.64% from -$995,474 recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Cash from Operations peaked at -$305,128 during Q2 2017, and registered a low of -$1.3 million during Q3 2020.
- Its 3-year average for Cash from Operations is -$829,068, with a median of -$752,863 in 2018.
- The largest annual percentage gain for Monopar Therapeutics' Cash from Operations in the last 5 years was 49.82% (2018), contrasted with its biggest fall of 159.67% (2018).
- Monopar Therapeutics' Cash from Operations (Quarterly) stood at -$816,021 in 2017, then spiked by 36.37% to -$519,212 in 2018, then dropped by 28.79% to -$668,705 in 2019, then plummeted by 112.07% to -$1.3 million in 2020.
- Its Cash from Operations stands at -$1.3 million for Q3 2020, versus -$995,474 for Q2 2020 and -$1.1 million for Q1 2020.